AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

Fampridine, used for improving walking in multiple sclerosis, may also enhance working memory in individuals with schizophrenia or depression.

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.